


Ledipasvir

Cat. No.:	HY-15602		
CAS No.:	1256388-51-8		
Molecular Formula:	C ₄₉ H ₅₄ F ₂ N ₈ O ₆		
Molecular Weight:	889		
Target:	HCV; SARS-CoV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (56.24 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.1249 mL	5.6243 mL	11.2486 mL
		5 mM	0.2250 mL	1.1249 mL	2.2497 mL
10 mM		0.1125 mL	0.5624 mL	1.1249 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.81 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.81 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC ₅₀ s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^{pro} inhibitor with an IC ₅₀ of 1.62 μM ^[3] .
IC₅₀ & Target	EC ₅₀ : 34 pM (GT1a), 4 pM (GT1b) ^[1]
In Vitro	Ledipasvir has GT1a and 1b EC ₅₀ values of 31 and 4 pM, respectively, and protein-adjusted EC ₅₀ values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC ₅₀ of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay ^[1] . Ledipasvir exhibits an EC ₅₀ value of 141 nM against the JFH/3a-NS5A replicon ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ledipasvir is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey and low predicted clearance in human. The pharmacokinetics of Ledipasvir is measured in rats and dogs. Ledipasvir shows good half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (V_{ss}) that are greater than total body water volume^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

Rats, Dogs and Monkeys^[1]

Pharmacokinetic studies are performed in male naïve Sprague-Dawley (SD) rats, non-naïve beagle dogs, and cynomolgus monkeys (three animals per dosing route). Intravenous (IV) administration is dosed via infusion over 30 min in a vehicle containing 5% ethanol, 20% PEG400, and 75% water (pH adjusted to 3.0 with HCl). Oral dosing is administered by gavage in a vehicle containing 5% ethanol, 45% PEG 400, and 50% of 50 mM citrate buffer, pH 3. Blood samples are collected over a 24 h period postdose into Vacutainer tubes containing EDTA-K2. Plasma was isolated, and the concentration of the test compound in plasma was determined with LC/MS/MS after protein precipitation with acetonitrile. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Signal Transduct Target Ther. 2021 May 29;6(1):212.
- Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1922-1927.
- J Gastroenterol. 2019 May;54(5):449-458.
- Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):867-876.
- Antimicrob Agents Chemother. 2015 Jun;59(6):3482-92.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Link JO, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. *J Med Chem.* 2014 Mar 13;57(5):2033-46
- [2]. Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. *J Clin Virol.* 2013 May;57(1):13-8.
- [3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. *Signal Transduct Target Ther.* 2021 May 29;6(1):212.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA